Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN
#Cardiovascular outcomes
MACE, HFpEF, CV death, the trials that move guidelines.
Explainer
MASLD and cardiovascular risk explained
MASLD affects 38% of adults worldwide and heart disease kills more of them than liver failure. Where semaglutide fits, and what remains unproven.
Explainer
Does the eGFR dip explain heart benefit?
A 376-patient Saudi cohort asked whether the early eGFR change explains heart outcomes on dapagliflozin plus semaglutide. The answer was no.
Explainer
Semaglutide and the cost of CV benefit
A 2026 cost-effectiveness review places semaglutide, a GLP-1 agonist, in the moderate tier for preventing cardiovascular events. Here is what that means.
Explainer
Semaglutide and heart risk: a 2026 review
A 2026 meta-analysis of 11 trials found semaglutide cut major cardiovascular events by about a third, similarly in people with and without diabetes.